Study in Patients With COPD
Phase 2
Completed
- Conditions
- COPDChronic Obstructive Pulmonary Disease
- Registration Number
- NCT00215423
- Lead Sponsor
- Dey
- Brief Summary
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
- Diagnosis of COPD
- History of cigarette smoking
Exclusion Criteria
- Clinical diagnosis of asthma
- Significant pulmonary disease other than COPD
- Other significant major organ disease(s)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Measure of lung function
- Secondary Outcome Measures
Name Time Method Change in lung function, as well as vital signs Physical Exam results, adverse event reporting, etc
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of action for the investigational drug in NCT00215423 COPD trial?
How does the investigational drug in NCT00215423 compare to standard-of-care therapies for COPD in terms of efficacy and safety?
What biomarkers were used in NCT00215423 to identify COPD patients most likely to respond to the investigational drug?
What adverse events were observed in NCT00215423 and how were they managed compared to control drug side effects?
What are the related compounds or combination therapies being explored for COPD treatment alongside the investigational drug in NCT00215423?
Trial Locations
- Locations (1)
Research Site
🇺🇸Medford, Oregon, United States
Research Site🇺🇸Medford, Oregon, United States